Tag: Typical antipsychotics

After Parkinson's disease, drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism, with prevalence rates up to 2.7% in some studies [1.3.3, 1.3.4]. Understanding which antipsychotics cause Parkinson's symptoms is crucial for patient safety and effective treatment.

In 2020, chlorpromazine, the generic form of Thorazine, was prescribed to approximately half a million people in the United States [1.2.2]. For those seeking alternatives, it's essential to understand what drug is similar to Thorazine and the available options.

Medication non-adherence among individuals with schizophrenia is a significant challenge, with reported rates ranging widely but averaging around 50%. For many, the cornerstone of treatment involves understanding what tablets do schizophrenics take and adhering to a personalized regimen of antipsychotic medication to manage core symptoms.

Antipsychotic medications are the cornerstone of treatment for managing symptoms of schizophrenia. However, there is no single "main" drug, as treatment is highly individualized and depends on the patient's symptoms, side-effect profile, and treatment response. The primary drug class used to treat **schizophrenia** is antipsychotics, which are categorized into several generations.

First approved for medical use in 1959, Stelazine (generic: trifluoperazine) is a conventional antipsychotic medication that was primarily used to treat schizophrenia and is also sometimes prescribed for the short-term management of severe anxiety. The brand name has been discontinued in the United States, but the generic form is still available for use.

First approved in 1967, the brand-name antipsychotic Navane is no longer marketed in the U.S. [1.7.2, 1.4.5]. This article explores the clinical and commercial reasons that answer the question: **Why was Navane discontinued?**